PRESS RELEASE
News
-
-
-
-
PRESS RELEASE
DBV Technologies conclut un accord avec la FDA sur les données d'innocuité requises pour la demande de BLA du patch Viaskin® Peanut chez les enfants de 4-7 ans, accélérant ainsi au premier semestre 2026 le dépôt de la demande…
DBV Technologies conclut un accord avec la FDA sur les données d'innocuité du patch Viaskin Peanut, anticipant un dépôt au 1er semestre 2026, et publie ses résultats financiers 2024 -
PRESS RELEASE
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...
DBV Technologies secures FDA agreement for Viaskin Peanut Patch BLA submission in 4-7-year-olds, accelerating launch timeline by approximately one year. Unaudited 2024 financial results reported -
-
-
-
PRESS RELEASE
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
DBV Technologies to participate in AAAAI/WAO Joint Congress to present long-term efficacy results of epicutaneous immunotherapy with VIASKIN peanut patch in peanut-allergic children aged 4-11 years, showcasing treatment benefits and high compliance rates -
